# Kanglin Biotec

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kanglin-biotec

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Website: www.kanglinbio.com
- Total disclosed funding: $21M
- Latest round: Series A (Nov 11, 2024)
- Investors on record: 2

## About

Based in Hangzhou, China, and founded in 2015, Kanglin Biotec operates as a developer of innovative gene therapy drugs, mainly engaged in the research and development of gene therapy and cell therapy technologies. The company has cooperated with Shanghai Public Health Clinical Center, Guangdong Medical University Affiliated Hospital, and Hangzhou First People's Hospital. It is a National High-Tech enterprise. In November 2024, Kanglin Biotec raised CNY 150 million in Series A funding from investors including ZJ Biomedicine and High-end Equipment Industry Fund and returning investor Zhejiang Miyin Investment. In September 2025, Kanglin Biotec closed series A+ funding from new investor China Taiping Insurance Group.

Kanglin Biotec specializes in innovative gene therapies aimed at addressing chronic ailments through functional cures. The company's technology platforms include adeno-associated virus vector platform, lentivirus vector platform, and hematopoietic stem cell vector platform. Its products focus on advanced genetic modification techniques that enables precise targeting of disease mechanisms, thereby improving patient outcomes in areas such as oncology, genetic disorders, and autoimmune diseases. 

The company generates revenue by providing technical services such as preparation of lentiviral vectors, T cell transduction and T cell gene editing.

The series A+ financing will accelerate the company R&D of innovative genetic drugs and enhance the company's competitiveness in the global biopharmaceutical industry.

## Funding rounds

- Series A, Nov 11, 2024, $21M — Zhejiang Miyin Investment, ZJ Biomedicine and High-end Equipment Industry Fund

## Investors

- Zhejiang Miyin Investment (https://capitalatlas.ai/funds/zhejiang-miyin-investment) — Series A
- ZJ Biomedicine and High-end Equipment Industry Fund — Series A